Le Lézard
Classified in: Health
Subject: AVO

Group Warns New Health "Conscience and Religious Freedom Division" Threatens Patients End-of-Life Care


WASHINGTON, Jan. 19, 2018 /PRNewswire-USNewswire/ -- Compassion & Choices today warned that the new "Conscience and Religious Freedom Division" in the U.S. Department of Health and Human Services (HHS) Office for Civil Rights threatens patients' legal rights to access all end-of life care options.

Dr. David Grube, National Medical Director, Compassion & Choices

The HHS "conscience protections" are designed to help healthcare providers "file a complaint under the Federal Health Care Provider Conscience Protection Statutes if you believe you have experienced discrimination because you ... Refused to provide health care items or services for the purpose of causing, or assisting in causing, the death of an individual."

"This new bureaucracy threatens to undermine the legal requirements under federal and state laws of healthcare providers to ensure their patients have access to all of their end-of-life options," said Kevin Díaz, national director of legal advocacy for Compassion & Choices, the nation's leading end-of-life care advocacy organization. "Healthcare providers have every right to opt out of providing healthcare services they object to for reasons of conscience or religious freedom. But they still have legal and moral obligation to fully inform their patients of all end-of-life options or refer them to another healthcare professional who will do so."

"We cannot allow physicians' conscience and religious beliefs to trump their patients' conscience and religious beliefs," said Dr. David Grube, Compassion & Choices National Medical Director, a family physician in Oregon who wrote prescriptions for medical aid in dying for about 15 patients between 1997 and his retirement in 2012. "This new federal bureaucracy seeks to threaten just that."

Last April, a federal judge dismissed a lawsuit by religious groups seeking to undermine Vermont's law authorizing medical aid in dying as end-of-life care option to peacefully end unbearable suffering for mentally capable, terminally ill adults with six months or fewer to live.

The plaintiffs alleged Vermont's Patient's Bill of Rights for Palliative Care and Pain Management violated their religious rights by requiring doctors to discuss all end-of-life care options with their patients. After U.S. District Court Judge Geoffrey W. Crawford granted Compassion & Choices intervenor status in the case, he ruled: "...physicians must inform patients about all choices and options relevant to their medical treatment." [See opinion here].

Compassion & Choices is the oldest nonprofit working to improve care and expand options for the end of life in the United States, with 450,000 supporters nationwide. For more information, visit: www.CompassionAndChoices.org.

Media Contacts: Sean Crowley, 202.495.8520, [email protected]

Latino Media: Patricia A. González-Portillo, 323.819.0310 [email protected]

Compassion & Choices logo. (PRNewsFoto/Compassion & Choices)

SOURCE Compassion & Choices


These press releases may also interest you

at 06:05
Global nonprofit BrightFocus Foundation announces $10 million in new Alzheimer's disease, macular degeneration, and glaucoma research grant funding?age-related diseases with no cure that affect more than 335 million people worldwide. This year's...

at 06:00
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to ?275 Million, Consisting of ?190 Million in Cash Upfront and up to ?85 Million in...

at 06:00
Dr. Luz Hernandez, a leading dentist in Tampa, Florida has redefined her practice to focus on facial aesthetics. Facial Aesthetics by Dr. Luz, https://www.drluzh.com/, provides a wide...

at 06:00
West Pharmaceutical Services, Inc. today announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance....

at 05:25
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...



News published on and distributed by: